Infinity Pharmaceuticals Financial Diagnostics

INFI -- USA Stock  

USD 2.00  0.01  0.50%

Infinity Pharmaceuticals diagnostics interface makes it easy to digest most current publicly released information about Infinity Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Infinity Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Infinity Pharmaceuticals Note

About 62.0% of the company shares are owned by institutional investors. The book value of Infinity Pharmaceuticals was currently reported as 0.85. The company recorded loss per share of 0.8. Infinity Pharmaceuticals had not issued any dividends in recent years. This company had 1:4 split on 2006-09-13. Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 22 people. To learn more about INFINITY PHARMACE call Adelene Perkins at 617-453-1000 or check out http://www.infi.com.

Infinity Pharmaceuticals Alerts

Infinity Pharmaceuticals generates negative expected return over the last 30 days
Infinity Pharmaceuticals has high historical volatility and very poor performance
Infinity Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 6 M. Net Loss for the year was (30.82 M) with loss before overhead, payroll, taxes, and interest of (14.83 M).
INFINITY PHARMACE currently holds about 49.16 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87.
Roughly 62.0% of the company shares are owned by institutional investors
Latest headline from nysedaily.com: Hot Stock on Radar Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals Upcoming Events

Upcoming Quarterly ReportFebruary 28, 2017
Next Earnings ReportMay 3, 2017

Infinity Pharmaceuticals Earning Estimates

EPSEstimate Date
Quarterly Estimate-0.56February 28, 2017
Infinity Pharmaceuticals normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Institutional Investors

Security TypeSharesValue
Blackrock IncCommon Shares972.3 K1.9 M
Dimensional Fund Advisors LpCommon Shares932.4 K1.8 M
Acadian Asset Management LlcCommon Shares372 K711 K
Gsa Capital Partners LlpCommon Shares289.9 K554 K
Essex Investment Management Co LlcCommon Shares164.6 K314 K
Wells Fargo CompanyCommon Shares97.8 K187 K
Clear Harbor Asset Management LlcCommon Shares95.6 K183 K
Citadel Advisors LlcCall Options58.9 K112 K
Citadel Advisors LlcPut Options13 K25 K

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 112.56 M.

Management Efficiency

Infinity Pharmaceuticals has return on total asset (ROA) of (28.6) % which means that it has lost $28.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (59.0) % meaning that it created substantial loss on money invested by shareholders.

Stock Holders for Infinity Pharmaceuticals

Technical Drivers

Infinity Pharmaceuticals retains Downside Deviation of 4.87 and Risk Adjusted Performance of 0.01. Infinity Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with intention to determine a pattern that calculates the direction of the corporation future prices. In other words you can use this information to find out if the corporation will indeed mirror its model of historical price patterns or the prices will eventually revert. We found eighteen technical drivers for Infinity Pharmaceuticals which can be compared to its competitors. Please check out Infinity Pharmaceuticals Standard Deviation as well as the relationship between Maximum Drawdown and Semi Variance to decide if Infinity Pharmaceuticals is priced fairly providing market reflects its last-minute price of 2.0 per share. Please also validate Infinity Pharmaceuticals Total Risk Alpha which is currently at 0.0 to confirm the company can sustain itself at future point.

Infinity Pharmaceuticals Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
  Portfolio Suggestion    
  
Execute Study
 
null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Infinity Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Infinity Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Infinity Pharmaceuticals Insider Trading Activities

Samuel Agresta over a week ago via Macroaxis 
Acquisition by Samuel Agresta of 300000 shares of Infinity Pharmaceuticals subject to Rule 16b-3
Anthony Evnin over a month ago via Macroaxis 
Acquisition by Anthony Evnin of 10000 shares of Infinity Pharmaceuticals subject to Rule 16b-3
Bvf Partners L P over a month ago via Macroaxis 
Purchase by Bvf Partners L P of 36825 shares of Infinity Pharmaceuticals
Michael Venuti over three months ago via Macroaxis 
Acquisition by Michael Venuti of 4000 shares of Infinity Pharmaceuticals subject to Rule 16b-3
Tasker Seth A over three months ago via Macroaxis 
Infinity Pharmaceuticals exotic insider transaction detected
Tasker Seth A over six months ago via Macroaxis 
Infinity Pharmaceuticals exotic insider transaction detected
Adelene Perkins over six months ago via Macroaxis 
Acquisition by Adelene Perkins of 500000 shares of Infinity Pharmaceuticals subject to Rule 16b-3
Kutok Jeffery over six months ago via Macroaxis 
Acquisition by Kutok Jeffery of 70000 shares of Infinity Pharmaceuticals subject to Rule 16b-3
Lawrence Bloch over six months ago via Macroaxis 
Infinity Pharmaceuticals exotic insider transaction detected
Bvf Partners L P over six months ago via Macroaxis 
Purchase by Bvf Partners L P of 1145 shares of Infinity Pharmaceuticals
Bvf Partners L P over six months ago via Macroaxis 
Purchase by Bvf Partners L P of 63042 shares of Infinity Pharmaceuticals
Tasker Seth A over a year ago via Macroaxis 
Infinity Pharmaceuticals exotic insider transaction detected

Infinity Pharmaceuticals Technical and Predictive Indicators

Infinity Pharmaceuticals Forecast Models

Recommendations

Infinity Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
2.0Hold3Odds
Infinity Pharmaceuticals current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Infinity Pharmaceuticals Analyst Advice  
Please also check Risk vs Return Analysis. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.